Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
DAPTO-SNAP: Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
Todd C. Lee MD MPH FIDSA
300 participants
Nov 14, 2024
INTERVENTIONAL
Conditions
Summary
This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)
Eligibility
Inclusion Criteria1
- Methicillin-resistant S. aureus bacteremia
Exclusion Criteria3
- Severe allergy or non-severe rash to vancomycin or daptomycin
- Suspected or confirmed MRSA pneumonia
- Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg/L or daptomycin MIC greater than or equal to 1mg/L
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Daptomycin given by injection at a dose determined by the treating team but not to be less than 6mg/kg
Vancomycin by injection to be given at a dose selected by the treating team to achieve a desired trough level or AUC-based target, as determined by local standards of care
Locations(14)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06637332